Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.